Trials / Unknown
UnknownNCT06395337
Multimodal Imaging in Rectal Cancer & Pancreatic Cancer
A Phase I/II Study to Evaluate the Safety and Feasibility of Multimodal Imaging Using a Dual-labeled Anti-CEA Antibody in Patients With Rectal or Pancreatic Cancer
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Most digestive cancers show (over)expression of the tumour marker carcinoembryonic antigen (CEA). Therefore, interest in CEA-targeting tracers has increased over the past years. CEA-targeting tracers can be used for preoperative, intra-operative and postoperative imaging purposes. This study focusses on both preoperative and intraoperative multimodal imaging and image-guided surgery in patients with rectal cancer or pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [111In]In-DOTA-ANTI-CEA antibody injection | tracer injection |
| RADIATION | SPECT/CT scan | abdominal and thoracic SPECT/CT scan |
| PROCEDURE | Resection surgery | oncological resection surgery will be performed extended with the use of dual-modality imaging. |
Timeline
- Start date
- 2024-05-02
- Primary completion
- 2025-05-02
- Completion
- 2025-06-02
- First posted
- 2024-05-02
- Last updated
- 2024-05-02
Locations
2 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT06395337. Inclusion in this directory is not an endorsement.